Paper34249367
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.
Cadegiani FA and 3 others. New Microbes New Infect, 2021. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. Papers, record 34249367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34249367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References61
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32360780 | Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. | Clin Microbiol Infect | 2020 | https://conductscience.org/library/papers/32360780 | PubMed |
| 2 | 34128772 | Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. | Pathog Glob Health | 2021 | https://conductscience.org/library/papers/34128772 | PubMed |
| 3 | 32901263 | Post COVID Syndrome (PCS) and healthcare workers: who cares for the carers? | QJM | 2020 | https://conductscience.org/library/papers/32901263 | PubMed |
| 4 | 32444366 | Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. | BMJ | 2020 | https://conductscience.org/library/papers/32444366 | PubMed |
| 5 | 14983848 | International ethical guidelines for biomedical research involving human subjects. | Bull Med Ethics | 2002 | https://conductscience.org/library/papers/14983848 | PubMed |
| 6 | 32007143 | Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. | Lancet | 2020 | https://conductscience.org/library/papers/32007143 | PubMed |
| 7 | 33643746 | Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). | Cureus | 2021 | https://conductscience.org/library/papers/33643746 | PubMed |
| 8 | 34084102 | Natural History and Clinical Course of Symptomatic and Asymptomatic COVID-19 Patients in the Kingdom of Saudi Arabia. | Saudi J Med Med Sci | 2021 | https://conductscience.org/library/papers/34084102 | PubMed |
| 9 | 32609307 | Excess Deaths From COVID-19 and Other Causes, March-April 2020. | JAMA | 2020 | https://conductscience.org/library/papers/32609307 | PubMed |
| 10 | 32451119 | The Early Natural History of SARS-CoV-2 Infection: Clinical Observations From an Urban, Ambulatory COVID-19 Clinic. | Mayo Clin Proc | 2020 | https://conductscience.org/library/papers/32451119 | PubMed |
| 11 | 32459916 | Hospitalization and Mortality among Black Patients and White Patients with Covid-19. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32459916 | PubMed |
| 12 | 33480414 | From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? | J Travel Med | 2021 | https://conductscience.org/library/papers/33480414 | PubMed |
| 13 | 34146226 | Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review. | Qual Life Res | 2021 | https://conductscience.org/library/papers/34146226 | PubMed |
| 14 | 33903131 | Prophylaxis against covid-19: living systematic review and network meta-analysis. | BMJ | 2021 | https://conductscience.org/library/papers/33903131 | PubMed |
| 15 | 33635829 | Increased COVID-19 infections in women with polycystic ovary syndrome: a population-based study. | Eur J Endocrinol | 2021 | https://conductscience.org/library/papers/33635829 | PubMed |
| 16 | 34145166 | Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. | Am J Ther | 2021 | https://conductscience.org/library/papers/34145166 | PubMed |
| 17 | 32031570 | Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. | JAMA | 2020 | https://conductscience.org/library/papers/32031570 | PubMed |
| 18 | 33089570 | Clinical symptoms of hyperandrogenic women diagnosed with COVID-19. | J Eur Acad Dermatol Venereol | 2021 | https://conductscience.org/library/papers/33089570 | PubMed |
| 19 | 32725286 | Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? | J Genet Eng Biotechnol | 2020 | https://conductscience.org/library/papers/32725286 | PubMed |
| 20 | 34167876 | Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. | Eur J Intern Med | 2021 | https://conductscience.org/library/papers/34167876 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41884792 | Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study). | Ther Adv Infect Dis | 2026 | https://conductscience.org/library/papers/41884792 | PubMed |
| 38197085 | Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review. | Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38197085 | PubMed |
| 37337731 | Comparison of COVID-19 Preprint and Peer-Reviewed Versions of Studies on Therapies for Critically Ill Patients. | J Intensive Care Med | 2023 | https://conductscience.org/library/papers/37337731 | PubMed |
| 36143420 | Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic. | Life (Basel) | 2022 | https://conductscience.org/library/papers/36143420 | PubMed |
| 35898916 | Microbiome-Based Hypothesis on Ivermectin's Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity. | Front Microbiol | 2022 | https://conductscience.org/library/papers/35898916 | PubMed |
| 35889004 | Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. | Microorganisms | 2022 | https://conductscience.org/library/papers/35889004 | PubMed |
| 35726131 | Ivermectin for preventing and treating COVID-19. | Cochrane Database Syst Rev | 2022 | https://conductscience.org/library/papers/35726131 | PubMed |
| 35359702 | Can anti-parasitic drugs help control COVID-19? | Future Virol | 2022 | https://conductscience.org/library/papers/35359702 | PubMed |
| 35299698 | Ivermectin and the Integrity of Healthcare Evidence During COVID-19. | Front Public Health | 2022 | https://conductscience.org/library/papers/35299698 | PubMed |
| 35163830 | Blood Bacteria-Free DNA in Septic Mice Enhances LPS-Induced Inflammation in Mice through Macrophage Response. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163830 | PubMed |
| 34976549 | Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial. | Cureus | 2021 | https://conductscience.org/library/papers/34976549 | PubMed |
| 34823008 | ESCMID COVID-19 living guidelines: drug treatment and clinical management. | Clin Microbiol Infect | 2022 | https://conductscience.org/library/papers/34823008 | PubMed |
| 34822026 | NSAIDs and Kelleni's protocol as potential early COVID-19 treatment game changer: could it be the final countdown? | Inflammopharmacology | 2022 | https://conductscience.org/library/papers/34822026 | PubMed |
| 34679203 | Antibiotics for the treatment of COVID-19. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/34679203 | PubMed |
| 34375047 | Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. | Am J Ther | 2021 | https://conductscience.org/library/papers/34375047 | PubMed |
| 34318930 | Ivermectin for preventing and treating COVID-19. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/34318930 | PubMed |
| 34145166 | Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. | Am J Ther | 2021 | https://conductscience.org/library/papers/34145166 | PubMed |
| 34088250 | NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. | Expert Rev Anti Infect Ther | 2022 | https://conductscience.org/library/papers/34088250 | PubMed |
| 33437562 | The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort. | Cureus | 2021 | https://conductscience.org/library/papers/33437562 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DPP4 | 1803 | PubTator's text mining | https://conductscience.org/library/genes/1803 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| OLFM4 | 10562 | PubTator's text mining | https://conductscience.org/library/genes/10562 | NCBI Gene |
| SLC25A18 | 83733 | PubTator's text mining | https://conductscience.org/library/genes/83733 | NCBI Gene |
| SLC5A2 | 6524 | PubTator's text mining | https://conductscience.org/library/genes/6524 | NCBI Gene |
| TMPRSS2 | 7113 | PubTator's text mining | https://conductscience.org/library/genes/7113 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34249367
GET https://conductscience.org/api/papers/v1/34249367/references?page=2